Maternal and perinatal outcomes in pregnant women with rheumatic diseases treated with biosimilar TNF inhibitors

Chícharo, Ana TeodósioLopes, Ana R.Barreira, SofiaPinto, LuísaMachado, Ana R. CruzCapela, Susana2024-12-062024-12-062024-01-012514-1775http://hdl.handle.net/10400.1/26402No safety or efficacy issues arose from using biosimilar TNFi during conception or pregnancy.engPregnancyRheumatic disordersMothersPerinatal periodTumor necrosis factor inhibitorsBiosimilar pharmaceuticalsMaternal and perinatal outcomes in pregnant women with rheumatic diseases treated with biosimilar TNF inhibitorsjournal article10.1093/rap/rkae044